R9644
利巴韦林
≥98% (TLC), IMP dehydrogenase inhibitor, powder
别名:
1-β-D-呋喃核糖基-1,2,4-三唑-3-甲酰胺
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C8H12N4O5
化学文摘社编号:
分子量:
244.20
UNSPSC Code:
12352202
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
利巴韦林, antiviral
SMILES string
NC(=O)c1ncn(n1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O
InChI
1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
InChI key
IWUCXVSUMQZMFG-AFCXAGJDSA-N
assay
≥98% (TLC)
form
powder
solubility
water: 19.60-20.40 mg/mL, clear, colorless to faintly yellow
antibiotic activity spectrum
viruses
mode of action
DNA synthesis | interferes
storage temp.
2-8°C
Quality Level
Gene Information
human ... IMPDH1(3614), IMPDH2(3615)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
抗病毒剂。其代谢产物利巴韦林 5′-磷酸，是肌苷一磷酸 (IMP) 脱氢酶的抑制剂。用于抑制嘌呤（GTP 池）在肌苷单磷酸 (IMP) 脱氢酶级别的生物合成，并作为抑制病毒RNA依赖性RNA聚合酶的二磷酸和三磷酸的前体。
用于抵御多种人类病毒感染的抗病毒剂，特别是慢性肝炎C、HIV 和腺病毒。其代谢产物利巴韦林 5′-磷酸，是肌苷一磷酸 (IMP) 脱氢酶的抑制剂。
用于抵御多种人类病毒感染的抗病毒剂，特别是慢性肝炎C、HIV 和腺病毒。其代谢产物利巴韦林 5′-磷酸，是肌苷一磷酸 (IMP) 脱氢酶的抑制剂，但也有实验证据支持许多其他作用机制。
General description
化学结构：核苷
嘌呤核苷酸生物合成中咪唑核苷酸中间体的类似物。
signalword
Danger
hcodes
Hazard Classifications
Muta. 2 - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
Michael Manns et al.
Lancet (London, England), 384(9954), 1597-1605 (2014-08-01)
An unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir (NS5A replication complex inhibitor) plus asunaprevir (NS3 protease inhibitor) in patients with genotype 1b infection
Fred Poordad et al.
The New England journal of medicine, 370(21), 1973-1982 (2014-04-15)
Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir
Chen-Hua Liu et al.
Annals of internal medicine, 159(11), 729-738 (2013-12-04)
Data are limited on the efficacy and safety of pegylated interferon plus ribavirin for patients with hepatitis C virus genotype 1 (HCV-1) receiving hemodialysis. To compare the efficacy and safety of combination therapy with pegylated interferon plus low-dose ribavirin and
Tao Meng et al.
Journal of virology, 88(10), 5803-5815 (2014-03-14)
In a screen for ribavirin resistance, a novel high-fidelity variant of human enterovirus 71 (EV71) with the single amino acid change L123F in its RNA-dependent RNA polymerase (RdRp or 3D) was identified. Based on the crystal structure of EV71 RdRp
Marie Pellerin et al.
Viruses, 13(3) (2021-04-04)
Hepatitis E virus (HEV) is considered as an emerging global health problem. In most cases, hepatitis E is a self-limiting disease and the virus is cleared spontaneously without the need of antiviral therapy. However, immunocompromised individuals can develop chronic infection
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持